

THE PATH IS CLEAR

6-MONTH DATA

89.8%

TARGET LESION
PRIMARY PATENCY




MERT WRAPSODY®
Cell-Impermeable Endoprosthesis



The **FIRST** and **ONLY** Cell-Impermeable* Endoprosthesis (CIE) that prevents transmural cellular migration and tissue accumulation.





INNOVATIVE COVERING WITH TRI-LAYERED MICROSTRUCTURE DESIGNED TO MAINTAIN LONG-TERM VESSEL PATENCY



1 NOVEL-SPUN INNER GRAFT LAYER

Reduces fibrin deposition and thrombus formation without coatings or drugs.²

*Novel-spun PTFE
microstructure of
WRAPSODY CIE*




*Traditional ePTFE
microstructure,
leading covered
stent manufacturer*


2 CELL-IMPERMEABLE MIDDLE LAYER*

Prevents transmural cellular migration and tissue accumulation.

WRAPSODY CIE



Leading Covered Stent



Cross-Sectional Histology Images: Left External Iliac, Animal, 180 days **Dolmatch, et al. JVIR. 2020; 31: 494–502.**
Evaluation of a Novel Spun Polytetrafluoroethylene Stent Graft in an Ovine External Iliac Artery Model¹

* Based upon evaluation of the device in an ovine external iliac artery model

3 BIOCOMPATIBLE ePTFE OUTER LAYER

Designed to allow tissue ingrowth to prevent endoprosthesis migration.




DESIGNED TO MAINTAIN LONG-TERM VESSEL PATENCY IN PATIENTS WITH OBSTRUCTIONS IN THE DIALYSIS OUTFLOW CIRCUIT.

OPTIMIZED RADIAL STRENGTH AND COMPRESSION RESISTANCE

The WRAPSODY CIE has consistent radial strength and robust local compression resistance across all diameter sizes, allowing the WRAPSODY CIE to withstand both intraluminal forces as well as extrinsic pressures placed on the device.

LOCAL COMPRESSION DEVICE COMPARISON²




WRAPSODY CIE versus 10 mm leading covered stent, each compressed by 1.8 N.

SOFTENED END ROWS

The WRAPSODY CIE has end rows with less radial force designed to better conform to healthy vessel tissue, prevent vessel trauma, and improve long-term patency.

Softened End Rows with less radial force.²

Nitinol Struts allow for upsizing of up to **25%** for superior vessel conformance.²




CLINICAL EVIDENCE


The six-month efficacy data is compelling and provides clinicians the chance to evaluate how WRAPSODY can help us prolong the vascular access of our patients. WRAPSODY should be the new standard of care for these patients.

– Mahmood K. Razavi, MD, FSIR, FSVM, Interventional Radiologist and Medical Director of Clinical Research at St. Joseph Heart and Vascular Center in Orange, Calif., and Co-Principal Investigator of the WAVE trial.

6-MONTH ARTERIOVENOUS FISTULA (AVF) TARGET LESION PRIMARY PATENCY – COVERED STENTS VS. PTA*



6-MONTH ARTERIOVENOUS GRAFT (AVG) TARGET LESION PRIMARY PATENCY – COVERED STENTS*




*Patency rates are defined differently; data comes from different individual studies and may differ in a head-to-head comparison, and therefore may not be predictive of clinical results.

MORE DIAMETER SIZES TO TREAT THE DIALYSIS OUTFLOW CIRCUIT

The WRAPSODY CIE is the only cell-impermeable endoprosthesis with 14 mm and 16 mm diameter options.

WRAPSODY CIE DIAMETERS



WRAPSODY CIE LENGTHS

The WRAPSODY CIE is available in lengths ranging from 30 mm to 125 mm.

6x125



16x30



ORDERING INFORMATION

Catalog Number	Catheter Working Length	WRAPSODY CIE Diameter	WRAPSODY CIE Length	French Size
WRAP-S06050/A	80 cm	6 mm	50 mm	8F
WRAP-S06075/A	80 cm	6 mm	75 mm	8F
WRAP-S06100/A	80 cm	6 mm	100 mm	8F
WRAP-S06125/A	80 cm	6 mm	125 mm	8F
WRAP-S07050/A	80 cm	7 mm	50 mm	9F
WRAP-S07075/A	80 cm	7 mm	75 mm	9F
WRAP-S07100/A	80 cm	7 mm	100 mm	9F
WRAP-S07125/A	80 cm	7 mm	125 mm	9F
WRAP-S08050/A	80 cm	8 mm	50 mm	9F
WRAP-S08075/A	80 cm	8 mm	75 mm	9F
WRAP-S08100/A	80 cm	8 mm	100 mm	10F
WRAP-S08125/A	80 cm	8 mm	125 mm	10F
WRAP-S09050/A	80 cm	9 mm	50 mm	10F
WRAP-S09075/A	80 cm	9 mm	75 mm	10F
WRAP-S09100/A	80 cm	9 mm	100 mm	11F
WRAP-S09125/A	80 cm	9 mm	125 mm	11F
WRAP-L06050/A	120 cm	6 mm	50 mm	8F
WRAP-L06075/A	120 cm	6 mm	75 mm	8F
WRAP-L06100/A	120 cm	6 mm	100 mm	8F
WRAP-L06125/A	120 cm	6 mm	125 mm	8F
WRAP-L07050/A	120 cm	7 mm	50 mm	9F
WRAP-L07075/A	120 cm	7 mm	75 mm	9F
WRAP-L07100/A	120 cm	7 mm	100 mm	9F
WRAP-L07125/A	120 cm	7 mm	125 mm	9F
WRAP-L08050/A	120 cm	8 mm	50 mm	9F
WRAP-L08075/A	120 cm	8 mm	75 mm	9F
WRAP-L08100/A	120 cm	8 mm	100 mm	10F
WRAP-L08125/A	120 cm	8 mm	125 mm	10F

Catalog Number	Catheter Working Length	WRAPSODY CIE Diameter	WRAPSODY CIE Length	French Size
WRAP-L09050/A	120 cm	9 mm	50 mm	10F
WRAP-L09075/A	120 cm	9 mm	75 mm	10F
WRAP-L09100/A	120 cm	9 mm	100 mm	11F
WRAP-L09125/A	120 cm	9 mm	125 mm	11F
WRAP-L10050/A	120 cm	10 mm	50 mm	11F
WRAP-L10075/A	120 cm	10 mm	75 mm	11F
WRAP-L10100/A	120 cm	10 mm	100 mm	12F
WRAP-L10125/A	120 cm	10 mm	125 mm	12F
WRAP-L12030/A	120 cm	12 mm	30 mm	12F
WRAP-L12040/A	120 cm	12 mm	40 mm	12F
WRAP-L12050/A	120 cm	12 mm	50 mm	12F
WRAP-L12060/A	120 cm	12 mm	60 mm	12F
WRAP-L12070/A	120 cm	12 mm	70 mm	12F
WRAP-L12080/A	120 cm	12 mm	80 mm	12F

EXCLUSIVE TO WRAPSODY CIE

Catalog Number	Catheter Working Length	WRAPSODY CIE Diameter	WRAPSODY CIE Length	French Size
WRAP-L14030/A	120 cm	14 mm	30 mm	12F
WRAP-L14040/A	120 cm	14 mm	40 mm	12F
WRAP-L14050/A	120 cm	14 mm	50 mm	12F
WRAP-L14060/A	120 cm	14 mm	60 mm	14F
WRAP-L14070/A	120 cm	14 mm	70 mm	14F
WRAP-L14080/A	120 cm	14 mm	80 mm	14F
WRAP-L16030/A	120 cm	16 mm	30 mm	14F
WRAP-L16040/A	120 cm	16 mm	40 mm	14F
WRAP-L16050/A	120 cm	16 mm	50 mm	14F
WRAP-L16060/A	120 cm	16 mm	60 mm	14F
WRAP-L16070/A	120 cm	16 mm	70 mm	14F
WRAP-L16080/A	120 cm	16 mm	80 mm	14F

REFERENCES

- Dolmatch et al. 2020. "Evaluation of a Novel Spun Polytetrafluoroethylene Stent Graft in an Ovine External Iliac Artery Model." *Journal of Vascular and Interventional Radiology* 21, no. 3 (March): 494-502. doi.org/10.1016/j.jvir.2019.07.036. (PMID: 31959517)
- Data on file.
- Razavi. "Six-month safety and efficacy outcomes from the randomized-controlled arm of the WRAPSODY® Arteriovenous Access Efficacy (WAVE) trial". PowerPoint presented at the annual Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scientific symposium, Lisbon, Portugal, September, 2024.
- Razavi. "Six-month safety and efficacy outcomes from the WRAPSODY® Arteriovenous Access Efficacy (WAVE) trial". PowerPoint presented at the annual VEITHsymposium, November, 2024.

Before using refer to Instructions for Use for indications, contraindications, warnings, precautions, and directions for use.



Understand. Innovate. Deliver.™

merit.com

Merit Medical Systems, Inc.
1600 West Merit Parkway
South Jordan, Utah 84095
1.801.253.1600
1.800.35.MERIT

Merit Medical Europe, Middle
East & Africa (EMEA)
Amerikalaan 42, 6199 AE
Maastricht-Airport
The Netherlands
+31 43 358 82 22

Merit Medical Ireland Ltd.
Parkmore Business Park West
Galway, Ireland
+353 (0) 91 703 733